Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
- The most cited comparison: retatrutide produced approximately 24.2% mean weight loss at 12 mg over 48 weeks in phase 2; tirzepatide produced approximately 22.5% at 15 mg over 72 weeks in SURMOUNT-1. The retatrutide figure is larger by about 1.7 percentage points.
- These are cross-trial averages, not a head-to-head comparison. The two trials had different durations, different population sizes (338 for retatrutide phase 2 vs 2,539 for SURMOUNT-1), and different protocols. Direct comparison is methodologically weak.
- Tirzepatide is FDA-approved with about four years of post-marketing safety data. Retatrutide is investigational with 48 weeks of phase 2 safety data. Tirzepatide has the better-characterized safety profile.
- "Better" is not a universal answer. For efficacy ceiling, retatrutide appears to have a small edge in early data. For safety certainty, availability, and insurance coverage, tirzepatide wins decisively today.
Direct answer
Cross-trial comparison suggests retatrutide produces slightly larger mean weight loss than tirzepatide (about 24.2% in phase 2 versus 22.5% in SURMOUNT-1 at maximum doses), but the comparison is not head-to-head, the trials had different durations and sizes, and the retatrutide curve had not plateaued at 48 weeks. Tirzepatide is FDA-approved with established multi-year safety data. Retatrutide is investigational with limited safety data and is not commercially available. Today, tirzepatide is the better choice for almost every patient. Whether retatrutide will be "better" after phase 3 data and post-marketing experience is unknown.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The most important caveat: no head-to-head trial exists
- Why cross-trial comparison is methodologically weak
- The weight loss numbers, contextualized
- Time-matched vs final-readout comparisons
- Side-by-side: efficacy, safety, availability, cost
- Mechanism differences and what they predict
- Liver fat: the area where retatrutide most clearly leads
- Side effects: where tirzepatide leads on tolerability
- The cardiovascular question
- The decision framework: today vs the future
- The contrary view: should anyone wait for retatrutide
- FAQ
- Sources
The most important caveat: no head-to-head trial exists
This article begins where most retatrutide vs tirzepatide articles end. There is no published clinical trial that compares retatrutide and tirzepatide in the same study population using the same protocol. All comparisons are cross-trial.
Cross-trial comparison is not the same as head-to-head comparison. The headline number "retatrutide produced 24.2% weight loss; tirzepatide produced 22.5%" treats these figures as if they came from a single comparative trial. They did not. They came from two different trials with different participants, different durations, different protocols, and different conditions of measurement.
Whenever you read "retatrutide is X percentage points better than tirzepatide," the appropriate mental footnote is: "in cross-trial comparison, where the methodology limits how much weight that comparison should carry."
Why cross-trial comparison is methodologically weak
The reasons cross-trial comparisons can mislead:
Different populations. The retatrutide phase 2 trial enrolled 338 adults with obesity or overweight with comorbidities. SURMOUNT-1 enrolled 2,539 adults with obesity. The two populations were similar but not identical. Different mean baseline BMI, different distributions of comorbidities, different geographic enrollment.
Different durations. Retatrutide phase 2 was 48 weeks. SURMOUNT-1 was 72 weeks. Weight loss curves shape over time differently. A 48-week measurement and a 72-week measurement are not the same data point.
Different trial-conduct conditions. Trial sites, monitoring rigor, run-in periods, and concomitant lifestyle interventions all affect outcomes. SURMOUNT-1 included structured lifestyle counseling. The retatrutide phase 2 trial protocol differs in some ways.
Different sample sizes. 338 participants in retatrutide phase 2 versus 2,539 in SURMOUNT-1. Smaller trials produce noisier estimates with wider confidence intervals. The retatrutide figure has more statistical uncertainty around it.
Different periods. SURMOUNT-1 conducted recruitment during 2019-2021, partly during the COVID pandemic. Retatrutide phase 2 ran 2021-2023, post-vaccine era. Background conditions of trial conduct differ.
Different sponsors but same sponsor. Both trials were sponsored by Eli Lilly, which reduces some between-trial variability but does not eliminate it.
The honest summary: cross-trial differences are real signals but not definitive evidence. A 1.7 percentage point difference in cross-trial comparison could reflect a real efficacy difference, a difference in trial conduct, statistical noise, or a combination. Without a head-to-head trial, the question cannot be definitively answered.
The weight loss numbers, contextualized
The figures you need to compare retatrutide and tirzepatide accurately:
| Drug, dose | Trial | N | Duration | Mean weight loss | ≥15% loss | ≥20% loss | ≥25% loss |
|---|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | SURMOUNT-1 | 2,539 | 72 weeks | ~22.5% | ~70% | ~57% | ~36% |
| Tirzepatide 10 mg | SURMOUNT-1 | 2,539 | 72 weeks | ~19.5% | ~63% | ~50% | ~28% |
| Tirzepatide 5 mg | SURMOUNT-1 | 2,539 | 72 weeks | ~15% | ~50% | ~32% | ~15% |
| Retatrutide 12 mg | Phase 2 | 338 | 48 weeks | ~24.2% | ~83% | ~63% | ~48% |
| Retatrutide 8 mg | Phase 2 | 338 | 48 weeks | ~22.8% | ~74% | ~58% | ~48% |
| Retatrutide 4 mg | Phase 2 | 338 | 48 weeks | ~17.1% | ~52% | ~36% | ~24% |
The retatrutide figures are larger across the response distribution. More participants achieved each threshold of weight loss. The difference is not just at the highest dose; mid-doses also performed strongly.
An important caveat: the retatrutide phase 2 trial weight loss curve had not plateaued at 48 weeks. The 12 mg arm was still losing weight at trial end. Extended duration may have produced larger weight loss. Conversely, phase 3 trials with larger populations sometimes show somewhat smaller effects than phase 2.
Time-matched vs final-readout comparisons
One way to address the duration mismatch is to compare time-matched results. Looking at tirzepatide's 48-week interim data from SURMOUNT-1 and retatrutide's 48-week data:
| Drug, dose, time | Approximate mean weight loss |
|---|---|
| Tirzepatide 15 mg at week 48 (SURMOUNT-1 interim) | ~20% |
| Retatrutide 12 mg at week 48 (phase 2) | ~24.2% |
At time-matched 48 weeks, the retatrutide advantage is more pronounced (about 4 percentage points). This is the most fair direct cross-trial comparison.
The reverse extrapolation is also possible: if retatrutide's curve had continued for an additional 24 weeks at the rate observed late in phase 2, the 72-week figure might have been substantially higher, perhaps 28-30%. This is extrapolation, not data. Phase 3 trials extending to longer durations will provide the actual answer.
Side-by-side: efficacy, safety, availability, cost
| Dimension | Tirzepatide | Retatrutide | Advantage |
|---|---|---|---|
| Mean weight loss (max dose) | ~22.5% (72 weeks) | ~24.2% (48 weeks, not plateaued) | Retatrutide (slight, cross-trial) |
| Population studied | ~2,500+ in pivotal trial | 338 in phase 2 | Tirzepatide (larger evidence base) |
| FDA approval status | Approved (2022 T2D, 2023 obesity) | Not approved, investigational | Tirzepatide |
| Years of human use | ~4 years on market | Phase 2 + ongoing phase 3 only | Tirzepatide |
| Long-term safety profile | Reasonable, expanding | Unknown beyond 48 weeks | Tirzepatide |
| Nausea rate (max dose) | ~29% | ~75% in phase 2 | Tirzepatide |
| Discontinuation rate (max dose) | ~7% | ~16% in phase 2 | Tirzepatide |
| Heart rate change | +2-5 bpm | +~6 bpm at 12 mg | Tirzepatide |
| Liver fat reduction | Strong | Strongest | Retatrutide |
| Lean mass preservation | Good | Similar or slightly better | Possibly retatrutide |
| Cardiovascular outcomes data | Pending (SURPASS-CVOT) | Pending (TRIUMPH-3) | Tie (both pending) |
| Commercial availability | Yes, brand and compounded routes have existed | None, not legal outside trials | Tirzepatide |
| Insurance coverage | Growing, varies by plan | None (not approved) | Tirzepatide |
| Cost | $1,060 list (Zepbound) | Unknown | Tirzepatide (known and accessible) |
The scorecard favors tirzepatide on most current dimensions. Retatrutide's advantage is primarily on efficacy ceiling and on hepatic fat reduction, both of which matter for specific patient populations but do not override the broader safety and availability differences.
Mechanism differences and what they predict
The mechanism difference between retatrutide and tirzepatide is one specific addition: retatrutide activates the glucagon receptor in addition to the GIP and GLP-1 receptors that tirzepatide already targets.
Predicted consequences of the glucagon receptor addition:
- More energy expenditure. Glucagon agonism increases basal metabolic rate. This is the proposed reason for retatrutide's somewhat larger weight loss.
- More hepatic fat reduction. Glucagon stimulates hepatic fatty acid oxidation. This explains retatrutide's strongest finding (the 80% relative reduction in liver fat).
- Modest increase in heart rate. Glucagon increases sympathetic tone, which raises heart rate. The 6 bpm signal observed in phase 2 is consistent with this prediction.
- Theoretical risk of hyperglycemia. Glucagon raises blood sugar in isolation. The retatrutide molecule balances this with strong GIP and GLP-1 effects; net glucose control has been favorable in trials.
- Slightly increased risk of certain side effects. Possibly larger GI burden, possibly different effects on the heart, possibly different long-term effects on the liver. Some of these are speculation, some are observed in phase 2.
Each mechanism addition is a double-edged sword. More receptor activity adds therapeutic effects but adds side effect surfaces. Retatrutide's mechanism is more comprehensive than tirzepatide's, which produces both the larger efficacy and the larger side effect profile.
Liver fat: the area where retatrutide most clearly leads
If there is one area where retatrutide's data is clearly stronger than tirzepatide's, it is hepatic fat reduction.
| Drug, dose | Relative reduction in liver fat at end of trial |
|---|---|
| Tirzepatide 15 mg (substudy) | ~50-60% |
| Retatrutide 12 mg (substudy) | ~80%+ |
The difference is large. The mechanism explanation is direct: the glucagon receptor component activates hepatic fat oxidation in a way that tirzepatide's GIP/GLP-1 alone cannot.
The clinical relevance: patients with metabolic-associated fatty liver disease (MAFLD) or steatohepatitis (MASH) may benefit more from retatrutide than from tirzepatide. Dedicated phase 3 trials for hepatic indications are ongoing.
For patients without significant hepatic steatosis, the liver fat difference is less directly relevant. Both drugs produce meaningful weight loss and metabolic improvement.
Side effects: where tirzepatide leads on tolerability
Tirzepatide is meaningfully better tolerated than retatrutide at maximum doses:
- Nausea: ~29% (tirzepatide 15 mg) vs ~75% (retatrutide 12 mg)
- Vomiting: ~9% (tirzepatide) vs ~39% (retatrutide)
- Discontinuation due to AE: ~7% (tirzepatide) vs ~16% (retatrutide)
- Heart rate increase: +2-5 bpm (tirzepatide) vs +~6 bpm (retatrutide)
The tolerability difference matters in two ways. First, more patients can tolerate the maximum tirzepatide dose than the maximum retatrutide dose. This affects real-world average effects. Second, the side effect burden during titration is heavier on retatrutide, which can affect quality of life during the active titration phase.
This is not a small consideration. A drug that produces 24.2% weight loss but is only tolerable for 84% of maximum-dose patients may produce smaller real-world average effects than a drug producing 22.5% with 93% tolerability. Tolerability is part of effectiveness.
The cardiovascular question
Both drugs have outstanding questions about long-term cardiovascular outcomes. Tirzepatide's SURPASS-CVOT trial is ongoing and will provide the answer for tirzepatide. Retatrutide's TRIUMPH-3 trial will provide the answer for retatrutide. Neither has reported.
The pre-existing context: semaglutide's SELECT trial (Lincoff et al., NEJM 2023) showed cardiovascular benefit in patients with obesity and established cardiovascular disease. This is a positive precedent for the incretin class.
Retatrutide's larger heart rate signal raises a flag that tirzepatide does not raise as prominently. Whether the heart rate signal translates to adverse cardiovascular outcomes or whether it is offset by the metabolic and weight-loss benefits is the question TRIUMPH-3 is designed to answer.
Until both trials report, patients with significant cardiovascular history should approach retatrutide with more caution than they need to approach tirzepatide. The data for tirzepatide is better characterized; the data for retatrutide has more unknowns.
The decision framework: today vs the future
For most patients in May 2026, the choice is not between retatrutide and tirzepatide. Retatrutide is not available. The choice is between tirzepatide today and a hypothetical retatrutide in 1-3 years.
If you are not on any incretin therapy and want to start now:
- Tirzepatide is the appropriate choice for maximum efficacy among approved options.
- Starting now produces real benefit. Waiting for retatrutide costs years of potential weight loss and metabolic improvement.
- When retatrutide is approved, switching can be discussed at that time.
If you are on semaglutide and have plateaued:
- Tirzepatide is the appropriate next step.
- Retatrutide is not currently available as a switch option.
If you are on tirzepatide at maximum dose and have plateaued:
- This is the profile most likely to benefit from retatrutide when available.
- Continue tirzepatide. Discuss potential clinical trial enrollment with your clinician.
- Plan for a possible switch in 2027-2029 depending on FDA approval timing.
If you have significant hepatic steatosis or MASH:
- Tirzepatide already provides hepatic benefit. Retatrutide may provide more.
- Tirzepatide is the right choice today.
- Retatrutide for hepatic indications may become available if dedicated trials succeed.
If you have significant cardiovascular history:
- The tirzepatide cardiovascular profile is better-characterized than retatrutide's.
- Until TRIUMPH-3 reports, tirzepatide carries less cardiovascular uncertainty.
- This consideration may favor tirzepatide even after retatrutide is approved.
The contrary view: should anyone wait for retatrutide
The case for waiting:
Argument 1: The efficacy difference might be larger than cross-trial data suggests. If phase 3 confirms a 4-5 percentage point advantage at matched durations, retatrutide becomes meaningfully better than tirzepatide.
Argument 2: The liver fat finding could be transformative for MASH patients. Patients with significant hepatic disease may have qualitatively different outcomes on retatrutide.
Argument 3: Younger patients have time to wait. A patient in their 30s with obesity-related health concerns but no acute decompensation can plausibly wait 2-3 years for retatrutide approval without losing meaningful health span.
The counter:
Counter 1: The efficacy difference might be smaller in phase 3. Phase 3 effects are usually smaller than phase 2 effects. The advantage could shrink to 1-2 percentage points or vanish.
Counter 2: Tirzepatide is producing benefit now. Two to three years of tirzepatide weight loss and metabolic improvement is real benefit. Waiting trades known benefit for hypothetical future benefit.
Counter 3: The retatrutide timeline could slip. Approval could come in 2027, 2028, 2029, or later. Patients planning around a specific date risk extended waiting.
Counter 4: Retatrutide will not be more affordable at launch. Insurance coverage for retatrutide will lag tirzepatide by years. The financial barrier to retatrutide will be at least as high as the current tirzepatide barrier.
The synthesis: For most patients, "tirzepatide now, consider retatrutide later" is the right framing. The exceptions are patients with specific clinical profiles (MASH, plateau on tirzepatide max dose, eligibility for clinical trial enrollment) where waiting or trial enrollment may make sense. The default position is not to wait.
FAQ
Is retatrutide better than tirzepatide? Cross-trial efficacy is slightly better with retatrutide (~24% vs ~22.5%), but tirzepatide is FDA-approved with established safety. "Better" depends on what you weight.
How much more weight do you lose on retatrutide vs tirzepatide? Cross-trial difference is about 1.7 percentage points at maximum doses, or about 4 percentage points at time-matched 48 weeks. Real-world differences may be smaller.
Has there been a head-to-head trial? No published head-to-head trial of retatrutide vs tirzepatide exists.
Can I switch from tirzepatide to retatrutide? Not currently. Retatrutide is not commercially available. The only legal U.S. path is clinical trial enrollment.
Is retatrutide safer than tirzepatide? No. Tirzepatide has more established safety data. Retatrutide has higher GI side effects and a larger heart rate signal in phase 2.
Why does retatrutide work better? Cross-trial data suggests modestly better efficacy, likely from the added glucagon receptor activity (energy expenditure plus hepatic fat oxidation).
Should I wait for retatrutide? Generally no. Start an approved therapy now if you meet criteria. Reconsider when retatrutide is approved.
Will retatrutide be cheaper than tirzepatide? Unlikely at launch. New drugs typically launch at similar or higher prices than predecessors. Long-term pricing depends on competition and insurance coverage.
Will retatrutide replace tirzepatide? Unlikely in the near term. Both will likely coexist as options. Tirzepatide will remain a major choice based on established profile, lower side effect burden, and broader insurance coverage.
Is one better for diabetes? Both reduce HbA1c substantially. Tirzepatide is FDA-approved for type 2 diabetes. Retatrutide's diabetes indication is under TRIUMPH-2 phase 3 study.
Which is better for liver fat? Retatrutide shows larger reductions in liver fat in phase 2 data, likely due to the glucagon receptor mechanism.
Are the side effects the same? Similar in type (GI primarily) but different in magnitude. Retatrutide phase 2 showed higher rates and a larger heart rate signal.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Rosenstock J et al. Retatrutide for type 2 diabetes: a phase 2 trial. Lancet. 2023.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Sanyal AJ et al. Effect of retatrutide on liver fat: Substudy results from the Phase 2 obesity trial. Nature Medicine. 2024.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism. 2022.
- ClinicalTrials.gov. TRIUMPH-1 through TRIUMPH-4 phase 3 trial registry entries. Accessed May 2026.
- ClinicalTrials.gov. SURPASS-CVOT cardiovascular outcomes trial entry. Accessed May 2026.
- FDA Drugs@FDA database. Tirzepatide approval records (Mounjaro 2022, Zepbound 2023). Accessed May 2026.
- American Association of Clinical Endocrinologists. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. 2024 update.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a digital telehealth platform connecting patients with independent licensed clinicians and U.S. state-licensed pharmacies. FormBlends does not manufacture, prescribe, or dispense medication directly. FormBlends does not sell, supply, or formulate retatrutide. Retatrutide is investigational and not FDA-approved as of May 2026. Tirzepatide is FDA-approved in brand form and is accessible as a compounded preparation through 503A pharmacies under specific federal regulations.
Compounded Medication Notice. Compounded tirzepatide accessed through FormBlends-connected 503A state-licensed compounding pharmacies is prepared in response to individual prescriptions. Compounded tirzepatide is not FDA-approved and has not undergone the same regulatory review as brand-name tirzepatide products (Mounjaro and Zepbound). Retatrutide is not legally available as a compounded preparation and is not offered through FormBlends.
Results Disclaimer. Cross-trial weight loss comparisons reference different trial populations, durations, and protocols. Differences between retatrutide phase 2 results (Jastreboff et al. 2023) and SURMOUNT-1 tirzepatide results (Jastreboff et al. 2022) should not be interpreted as equivalent to head-to-head comparisons. Phase 3 retatrutide results may differ from phase 2 averages. Individual response to any incretin therapy varies substantially.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. SURMOUNT and SURPASS are trial program names used by Eli Lilly. TRIUMPH is the trial program name for retatrutide phase 3 development. Retatrutide is the international nonproprietary name for an Eli Lilly investigational compound (LY3437943) and has no current U.S. brand name. FormBlends is not affiliated with Eli Lilly, Novo Nordisk, the FDA, or any sponsor of the cited clinical trials.